  This study aimed to: evaluate long-term toxicity and pharmacokinetic parameters; to identify the target organ of toxicity of a recombinant adenovirus<pathogen> vaccine expressing human<pathogen> papillomavirus<pathogen> 16 E6 and E7 proteins ( HPV16 E6E7-Ad5 Vac) in primates; and to determine the specific immune response of this recombinant adenovirus<pathogen> vaccine. HPV16 E6E7-Ad5 Vac ( dose 4.68 × 10 The macaques of both the high-dose group and the low-dose group did not exhibit any systemic toxic response. The administered safe dose of the vaccine was 4.68 × 10